A Pilot Trial of Dopamine Replacement for Dynamic Facial Expressions in Parkinson's Disease.
Rachel N SchadeUtaka SpringerAnia MikosDidem GokcayAlexandra ClarkChristine SapienzaHubert H FernandezMichael S OkunDawn BowersPublished in: Movement disorders clinical practice (2022)
The effects of levodopa on Parkinson's disease voluntary facial movement and on timing were robust and consistent with those of levodopa on other intentional movements in Parkinson's disease. This improvement possibly occurred because of levodopa enhanced activation of face representation areas in fronto-cortical regions or because of less movement-based suppression.